Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)
- 30 April 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 48 (1) , 121-127
- https://doi.org/10.1016/j.lungcan.2004.10.008
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectivenessEuropean Journal Of Cancer, 2001
- Single agent Gemcitabine for elderly patients with non small cell lung cancer (NSCLC): A phase II studyLung Cancer, 2000
- Geriatric oncologyEuropean Journal Of Cancer, 2000
- Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer A multicenter phase II studyLung Cancer, 2000
- Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatinCancer, 1999
- 82 Treatment of advanced and disseminated non small lung cancer (NSCLC) in elderly patients: Results of the MIC regimenLung Cancer, 1997
- Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II studyEuropean Journal Of Cancer, 1997
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ FunctionsJapanese Journal of Cancer Research, 1995
- Polychemotherapy in advanced non small cell lung cancer: a meta-analysisThe Lancet, 1993